Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc. (DAWN) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
dawn · stock forecast · 12 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 12 Wall Street analysts in the past 3 months
Buy
12 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$21.50
Consensus
$21.50
-0.1% upside
Low
$21.50
Median: $21.5 · Last Close: $21.53
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $21.52 | ↓ 0.04% |
1-day model range: $21.52–$21.53. Peak: $21.53 (-0.04%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · DAWN · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-11 | JP Morgan | Downgrade ↓ | Overweight→Neutral |
| 2026-03-10 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2026-03-09 | Wedbush | Downgrade ↓ | Outperform→Neutral |
| 2026-03-06 | Jones Trading | Downgrade ↓ | Buy→Hold |
| 2026-03-06 | Needham | Downgrade ↓ | Buy→Hold |
| 2026-02-25 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-02-25 | Wedbush | Maintains | Outperform→Outperform |
| 2026-02-25 | Needham | Maintains | Buy→Buy |
| 2025-11-24 | Needham | Maintains | Buy→Buy |
| 2025-11-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Day One Biopharmaceuticals, Inc. (DAWN) stock. Of the recent 78 rating actions, 1 were upgrades and 6 were downgrades. 12 analysts currently cover DAWN.
Analyst Recommendation Trends
DAWN analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$240M
↓ 39.7% YoY
Revenue Next Year
$308M
↑ 28.1% YoY
EPS This Year
$-0.78
EPS Next Year
$-0.18
↓ 76.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast DAWN EPS of $-0.78 for the current fiscal year, based on estimates from 6 analysts. The DAWN revenue forecast is $240M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The DAWN stock forecast is supported by two independent data sources: analyst consensus ratings from 12 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus DAWN price target is $21.50 (-0.1% upside), with an analyst consensus of Buy.
The DAWN short-term stock prediction for tomorrow is $21.52 (-0.04%).
Day One Biopharmaceuticals, Inc. trades on NASDAQ under the ticker DAWN. The DAWN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
DAWN forecast · 8 questionsAccording to 12 Wall Street analysts, the average 12-month DAWN price target is $21.50, with a high forecast of $21.50 and a low of $21.50. The median price target is shown in the chart above when available. This implies -0.1% potential upside from the current price of $21.53.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.